Changchun BCHT Biotechnology Co.SSE: 688276

2025 Semi-annual Report

Aug 30, 2025 · Issued by Changchun BCHT Biotechnology Co. via Shanghai Stock Exchange

Filed with SSE · Aug 30, 2025

On 6ix: 6ix.com/news/2025-semi-annual-report-380

2025 Semi-annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Changchun BCHT Biotechnology Co. on 6ix

Earlier from Changchun BCHT Biotechnology

Announcement on Voluntary Disclosure of Approval of Marketing Authorization Application for Live Attenuated Nasal-Spray Influenza VaccineAug 26, 2025
Announcement on Convening the 2025 Semi-annual Performance BriefingAug 23, 2025
Announcement on the Return of Raised Funds Formerly Used to Temporarily Supplement Current Capital and Use of Partial Idle Raised Funds to Temporarily Supplement Current CapitalJul 26, 2025
Announcement on Voluntary Disclosure of Obtaining Approval of Clinical Trial for Split-Virion Influenza Vaccine (BK-01 Adjuvant)Jun 20, 2025
Announcement on Implementation of Dividend Distribution for 2024Jun 11, 2025

Later from Changchun BCHT Biotechnology

Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025Sep 17, 2025
Announcement on Release of Freezing of Some Shareholders' SharesSep 25, 2025
Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2025 Semi-annual ReportSep 30, 2025
Announcement on Voluntary Disclosure of Approval for Diphtheria, Tetanus, Pertussis (Acellular, Component) and Haemophilus Type b Conjugate Vaccine, AdsorbedOct 10, 2025
Announcement on Voluntary Disclosure of Approval for Clinical Trial Application of Trivalent Influenza Virus Subunits Vaccine (BK-01 Adjuvant)Oct 14, 2025

All Changchun BCHT Biotechnology news releases

Follow Changchun BCHT Biotechnology into a list and get an email when it puts out news.

Follow Changchun BCHT Biotechnology